Development and validation of QDiabetes-2018 risk prediction algorithm to estimate future risk of type 2 diabetes: cohort study
BMJ 2017; 359 doi: https://doi.org/10.1136/bmj.j5019 (Published 20 November 2017) Cite this as: BMJ 2017;359:j5019
All rapid responses
Rapid responses are electronic comments to the editor. They enable our users to debate issues raised in articles published on bmj.com. A rapid response is first posted online. If you need the URL (web address) of an individual response, simply click on the response headline and copy the URL from the browser window. A proportion of responses will, after editing, be published online and in the print journal as letters, which are indexed in PubMed. Rapid responses are not indexed in PubMed and they are not journal articles. The BMJ reserves the right to remove responses which are being wilfully misrepresented as published articles or when it is brought to our attention that a response spreads misinformation.
From March 2022, the word limit for rapid responses will be 600 words not including references and author details. We will no longer post responses that exceed this limit.
The word limit for letters selected from posted responses remains 300 words.
Sir,
The article on QDiabetes 2018 made for interesting reading. (1) Although the new models are definitely better than the previous one, there are several points to consider:
1. Model B best explained the variation in time to diagnosis of type 2 diabetes (R2 [women]: 63.3%; [men]: 58.4%). This model included fasting blood sugar in addition to the basic model. However, only 14% of the subjects had a recorded fasting blood sugar value.
2. Model C was the next best, explaining 60.3% and 55.5% of variation in time to diagnosis of type 2 diabetes among women and men respectively. However, HbA1c values were recorded for only 6.2% subjects.
3. The ethnicity was recorded for 72.5% of subjects, of which 87.2% were white, while 2.3% were Indian. The actual proportions in the study population amount to 63.2% and 1.7% respectively. These proportions are representative of the general population in the UK, but far removed from the population composition of the two most populous countries- China and India. The authors do not suggest that the models can be applied to other populations, however, they do state that the algorithms used in the previous iteration have been ‘independently and externally validated in international populations and compared with other diabetes risk prediction models and been shown to have best performance’. (1) This naturally raises the possibility that Qdiabetes 2018 will be applied in foreign populations with different ethnicities and risk profiles. Considering that ethnicity is an important risk factor in the development of diabetes, the lack of non-white subjects is a matter of concern for workers outside the UK. (2) Given these limitations, one must exercise caution in applying the new model(s) outside the UK.
4. Only 14.9% of subjects had a family history of diabetes. In populations where this proportion is higher- 16.9% in India, for instance- the model will likely perform differently.(3) The extent of variation will have to be carefully ascertained before large-scale usage in such countries.
5. Among women subjects, the Adjusted Hazard Ratios show a consistent decline from Model A through Model C for all ethnicities except Black Africans, for whom the hazard ratio is higher in Model B. However, although a similar general trend is observed in men subjects, the hazard ratio increases for several variables in Model B.(1) Thus, the inclusion of Fasting Blood Sugar values in the basic model (Model A) seems to vary the risk differently for men and women.
6. As pointed out by the authors themselves, both Model B and Model C require further external validation before they can be used by clinicians. (1)
In summary, the authors must be commended for developing new models that better predict the risk of developing Type 2 diabetes. However, the said models must be used with caution outside the UK in view of the points raised above.
References:
1. Hippisley-Cox J, Coupland C. Development and validation of QDiabetes-2018 risk prediction algorithm to estimate future risk of type 2 diabetes: cohort study. BMJ [Internet]. 2017 [cited 2017 Nov 27];359. Available from: http://www.bmj.com/content/bmj/359/bmj.j5019.full.pdf
2. Kaveeshwar SA, Cornwall J. The current state of diabetes mellitus in India. Australas Med J [Internet]. 2014 [cited 2017 Nov 27];7(1):45–8. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3920109/pdf/AMJ-07-40.pdf
3. Ramachandran A, Snehalatha C, Kapur A, Vijay V, Mohan V, Das AK, et al. High prevalence of diabetes and impaired glucose tolerance in India: National Urban Diabetes Survey for the Diabetes Epidemiology Study Group in India (DESI). [cited 2017 Nov 27]; Available from: https://link.springer.com/content/pdf/10.1007/s001250100627.pdf
Competing interests: No competing interests
We read with Interest this article on QDiabetes-2018. Incorporation of new factors add further validity to the study as correctly mentioned by the authors. We wish to know whether risk varies across all ethnicities for each newly incorporated risk factor especially with statin use,antipsychotic usage and in subjects with GDM and PCOS. This algorithm may find a definite place in Asian countries like China and India where incidence is quite high.
Competing interests: No competing interests
Very important albeit overlooked variables: age, central obesity, and acanthosis nigricans
The article is highly relevant in day-to-day clinical practice. The incidence of Type 2 DM is highly influenced by other important albeit overlooked variables: age (increase with increasing age, increase with increase in central obesity, particularly intra-abdominal fat, and increase with presence of acanthosis nigricans, the cutaneous manifestation of insulin resistance). I am sure c-statistic could have been much improved, if these easily and clinically measured variables could have been included in the analysis.
In future, analysis of these easily and clinically measured variables, could be considered with advantage.
rajeevsavita.gupta@gmail.com
Competing interests: No competing interests